Substance / Medication

Pirtobrutinib

Overview

Active Ingredient
pirtobrutinib
RxNorm CUI
2629338
Labeler: Eli Lilly and CompanyUpdated: 2025-12-04T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown Jennifer R, Nguyen Bastien, Desikan Sai Prasad et al. · Blood · 2026
PMID: 41055698TrialFull text (PMC)
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.
Shah Nirav N, Zinzani Pier Luigi, Wang Michael et al. · Blood Adv · 2025
PMID: 40845254TrialFull text (PMC)
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
Mato Anthony R, Woyach Jennifer A, Brown Jennifer R et al. · N Engl J Med · 2023
PMID: 37407001Trial
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Mato Anthony R, Shah Nirav N, Jurczak Wojciech et al. · Lancet · 2021
PMID: 33676628TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pirtobrutinib (substance)
SNOMED CT
1351539006
UMLS CUI
C5554559
RxNorm CUI
2629338
Labeler
Eli Lilly and Company

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Pirtobrutinib: Uses, Evidence & Side Effects | Ltrl